Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ticagrelor sustained release - Synokem Pharmaceuticals

Next Previous
X
Search
Drug Profile

Ticagrelor sustained release - Synokem Pharmaceuticals

Alternative Names: Ticagrelor SR

Latest Information Update: 28 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Synokem Pharmaceuticals
  • Class Amines; Anti-infectives; Antianaemics; Antibacterials; Antithrombotics; Azoles; Cardiovascular therapies; Cyclopropanes; Fluorobenzenes; Purine nucleosides; Pyrimidines; Ribonucleosides; Small molecules; Vascular disorder therapies
  • Mechanism of Action Platelet ADP receptor antagonists; Purinoceptor P2Y12 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Myocardial infarction

Most Recent Events

  • 28 Apr 2024 No recent reports of development identified for preclinical development in Myocardial-infarction in India (PO, Tablet)
  • 06 Mar 2020 Preclinical trials in Myocardial infarction in India (PO)
  • 06 Mar 2020 Synokem Pharmaceuticals plans a phase III trial for Myocardial infarction in India (CTRI/2020/03/023925)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top